Source comparison
MK-677 for Muscle Tear: Compound Comparison
MK-677 (Ibutamoren) Growth hormone secretagogue. Stimulates endogenous GH pulsatile release 40–90% increase at 25mg daily Indirect via IGF-1. Promotes organized collagen alignment during remodeling phase 20–25mg daily for 8–12 weeks Best suited for sustained a
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Growth hormone secretagogue. Stimulates endogenous GH pulsatile release
- 40–90% increase at 25mg daily
- Indirect via IGF-1. Promotes organized collagen alignment during remodeling phase
- 20–25mg daily for 8–12 weeks
- Best suited for sustained anabolic environment during prolonged recovery. Requires consistency but avoids injection protocols
- BPC-157
- Pentadecapeptide. Enhances angiogenesis and fibroblast migration to injury site
- Minimal direct IGF-1 effect
- Direct stimulation of collagen deposition and vascular endothelial growth factor (VEGF) expression
- 250–500mcg daily subcutaneous injection
- Faster observable effect on acute injury (days 5–10). More targeted for localized soft tissue repair but requires injection near injury site
- TB-500 (Thymosin Beta-4)
- Actin-binding peptide. Promotes cell migration and reduces inflammation
- No IGF-1 elevation
- Increases collagen flexibility and reduces fibrosis through upregulation of matrix metalloproteinases
- 2–5mg twice weekly subcutaneous injection
- Excellent for preventing scar tissue rigidity. Often stacked with BPC-157 in research protocols targeting mobility preservation post-injury
- Exogenous IGF-1 (Mecasermin)
- Direct IGF-1 receptor agonist
- 100%+ receptor saturation during administration window
- Potent anabolic effect but risk of disorganized tissue growth if dosed improperly
- Research-only. Highly regulated due to abuse potential
- Most potent option but carries significant risk. Not recommended outside clinical oversight due to hypoglycemia risk and off-target tissue effects